Saturday, August 18, 2018
 
 
Company News: Page (1) of 1 - 07/31/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Union Medical Healthcare and Biotechnology Company Avalon Genomics Agree to Strategic Collaboration

(July 31, 2018)


EQS-News / 31/07/2018 / 07:00 UTC+8

FOR IMMEDIATE RELEASE
/
Union Medical Healthcare and Biotechnology Company Avalon Genomics
Agree to Strategic Collaboration

(30 July 2018, Hong Kong) Union Medical Healthcare Limited ("Union Medical Healthcare" or the "Company", together with its subsidiaries, the "Group", SEHK stock code: 2138), a leading integrated medical group in Hong Kong, is pleased to announce that the Group has entered into a strategic collaboration agreement with Avalon Genomics (HK) Limited ( "AGHK"), which is wholly owned by Avalon Genomics Limited ("Avalon Genomics"), expanding its services to genetic testing.

Avalon Genomics is a biotechnology company primarily engaged in the business of genetic laboratories, genetic testing and related development and research. Pursuant to the Agreement, AGHK granted the Company the exclusive right in the health check business sector in Hong Kong, subject to the terms of the Agreement, to distribute, promote, market and sell the genetic and genomic tests developed and offered by AGHK, which assess the genetic risks for various diseases of human beings including but not limited to autoimmune diseases, cancers, heart and vascular diseases, metabolic diseases and respiratory diseases. Meanwhile, the Group has entered into an agreement to acquire a minority stake in Avalon Genomics as a strategic investor.



Mr. Eddy Tang, Chairman, Executive Director and Chief Executive Officer of Union Medical Healthcare, said, "The Group has been extending its reach to and investment in other medical disciplines to enhance its service portfolio offering. We are pleased that Avalon Genomics has granted the exclusive right and agreed to work in strategic collaboration with us. Avalon Genomics is founded by a group of reputable scientists, biotechnologists and medical doctors who share a vision of people advancing healthcare of society through novel genetic research. Their vision coincides with our core values about developing precision medicine and preventive medical services. Through the collaboration, both Avalon Genomics and Union Medical Healthcare will be able to create synergy by leveraging our respective talents and resources, thus delivering a full array of quality services to clients."

- End -

 

About Union Medical Healthcare Limited
Union Medical Healthcare is principally engaged in the provision of one-stop medical and health care services in the Greater China via its 54 clinics and servicing centres with an aggregate service floor area of 200,000 sq. ft. The Group provides a full range of services and products under our well-recognised brands, including those of its one-stop aesthetic medical solutions provider DR REBORN, chiropractic services centre SPINE Central, health management and vaccination centre re:HEALTH and comprehensive dental centre UMH DENTAL CARE. Of which DR REBORN is recognised by "Hong Kong Top Service Brand Award" that is jointly organised by Hong Kong Brand Development Council and The Chinese Manufacturers' Association of Hong Kong. The Group is the largest aesthetic medical service provider in Hong Kong in terms of revenue in 2017.

For further information, please contact:
iPR Ogilvy & Mather

Callis Lau / Molisa Lau / Maggie Chui / Francesca Yeung
Tel: (852) 2136 6952 / 2136 6953 / 2136 8059 / 3920 7639
Fax: (852) 3170 6606
Email: [email protected]

31/07/2018 Dissemination of a Financial Press Release, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

Media archive at www.todayir.com

show this

Page: 1


Related Keywords:
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • Neurovascular Devices Market High Revenue at USD 24,650 mn by 2023 | Therapeutic Application Hemorrhagic & Ischemic Strokes | Worldwide Segmentation by MRFR
  • The Alzheimer's Research and Prevention Foundation (ARPF) Announces Second Brain Longevity® Therapy Training Program in Washington D.C.
  • Image Guided Radiotherapy Market to Experience Unfaltering Growth at 15.8% CAGR to Revolutionize the Healthcare Sector by 2023
  • Disposable Negative Pressure Wound Therapy Devices Market: Global Industry Analysis (2012 - 2016) & Opportunity Assessment (2017 - 2027)
  • Elysium Health™ Announces Exclusive License for Use of Nicotinamide Riboside for the Slowing of Aging and Prevention of Age-Related Diseases from Mayo Clinic and Harvard

    Cancer
  • Biotest AG: Cytotect(R) CP prevents transmission of Cytomegalovirus (CMV) to the unborn baby in pregnant women who are infected with CMV for the first time
  • ViewRay Announces Full Exercise of Underwriters' Option to Purchase Additional Shares and Closing of Public Offering of Common Stock
  • Mirati Therapeutics Announces Presentation Of KRAS G12C Chemistry Advances At The 255th American Chemical Society (ACS) National Meeting And Exposition
  • Agenus Receives Second Milestone Payment from Merck
  • Colorado Pain Care Broadens Practice to Include Cancer Patient Treatment in Denver, CO and Surrounding Area
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines